Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Affimed Therapeutics AG. (9/17/14). "Press Release: Affimed Announces Closing of Initial Public Offering". Heidelberg.

Region Region United States (USA)
Organisations Organisation Affimed Therapeutics AG
  Group Affimed (Group)
  Organisation 2 Jefferies Group Inc.
  Today Jefferies LLC
  Group Leucadia (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 investment banking
Index term Index term Affimed–SEVERAL: investment, 201405–201409 IPO $56m+$8.4m offering 8m+1.2m common shares $7/share at Nasdaq
Person Person Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
     


Affimed Therapeutics today announced the closing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares from Affimed at the public offering price, less underwriting discounts. Affimed's common shares are listed on the NASDAQ Global Market under the symbol "AFMD."

Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. acted as joint bookrunning managers for the offering. Trout Capital LLC acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 11, 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Telephone: (877) 547-6340, Email: Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, Telephone: (800) 808-7525, ext. 6142, Email: syndicate@leerink.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About Affimed

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, nextgeneration bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

Contact:

Affimed Therapeutics
Adi Hoess, CEO
Phone: +49 6221 65307-0
E-Mail: IR@affimed.com

   
Record changed: 2017-04-02

Advertisement

Picture Sacura Get Your Substance to Market iito 600x60px

More documents for Affimed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top